- Shares of Idera Pharaceuticals (IDRA) are up 20% before the open on heavy volume in response to the firm's report of positive phase 2 clinical trial results for it psoriasis drug IMO-8400.
- The 32-patient study met its primary endpoint of safety and tolerability over a 12-week period. No adverse events, dose reductions or discontinuations occurred.
- The study also met its secondary endpoint of demonstrating clinical activity as assessed by Psoriasis Area and Severity Index (PASI) scores.
- IMO-8400 has demonstrated activity in other autoimmune diseases such as lupus and arthritis.
at Zacks.com (Dec 31, 2014)